Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations

Pacific Biosciences of California (NASDAQ:PACB) Full Year 2024 Results

Key Financial Results

• Revenue: US$154.0m (down 23% from FY 2023).
• Net loss: US$308.7m (flat on FY 2023).
• US$1.12 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Pacific Biosciences of California EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 15%.

In the last 12 months, the only revenue segment was Integrated Platform for Genetic Analysis contributing US$154.0m. Notably, cost of sales worth US$106.3m amounted to 69% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$175.0m (49% of total expenses). Explore how PACB's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are up 19% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Pacific Biosciences of California you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.